Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - measles, mumps, rubella and varicella vaccine (live, attenuated) - powder for solution for injection (s.c./1.m.) - 0.5 ml

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - dutasteride - softgel capsule - 500 mcg

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - recombinant hepatitis b vaccine - suspension for injection (im) - 10 mcg/0.5 ml

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - lamotrigine - dispersible/chewable tablet - 5 mg

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - pneumococcal polysaccharide conjugate vaccine (adsorbed) - suspension for injection - 0.5ml

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - pneumococcal polysaccharide conjugate vaccine (adsorbed) - suspension for injection (im) - each 0.5 ml dose contains: 1 mcg of polysaccharide for serotypes 1 1,2, 5 1,2, 6b 1,2, 7f1.2, 9v 1,2, 14 1,2 and 23f 1,2 and 3 mcg of serotypes 4 1,2, 18c 1,3, and 19f 1,4 'adsorbed on aluminium phosphate 500 mcg a 13+ 2conjugate to protein d (derived from non-typeable haemophilus influenzae) carrier protein eq. to 9-16 mcg 3conjugate to tetanus toxoid carrier protein eq. to 5-10 mcg 4conjugate to diphtheria toxoid carrier protein e.q. to 3-6 mcg

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2024 strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains:* a/sydney/5/2021 (h1n1)pdm09-like strain 15 μg ha** (a/sydney/5/2021, ivr-229) a/darwin/9/2021 (h3n2)-like strain 15 μg ha** (a/darwin/6/2021, ivr-227) b/austria/1359417/2021-like strain 15 μg ha** (b/austria/1359417/2021, bvr-26) [victoria lineage] b/phuket/3073/2013-like strain 15 μg ha** (b/phuket/3073/2013, wild type) [yamagata lineage] *propagated in embryonated eggs **haemagglutinin

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - pneumococcal polysaccharide and non-typeable haemophilus influenzae (nthi) protein d conjugate vaccine, adsorbed - suspension for injection - 0.5ml

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines inc.; distributor: glaxosmithkline philippines inc. - belimumab - powder for solution for injection (iv infusion) - 120 mg vial each vial contains a sufficient amount of belimumab to deliver 120 mg in 1.5 ml when reconstituted as recommended with sterile water for injections. after reconstitution, each ml of solution contains 80 mg belimumab. 400 mg vial each vial contains a sufficient amount of belimumab to deliver 400 mg in 5.0 ml when reconstituted as recommended with sterile water for injections. after reconstitution, each ml of solution contains 80 mg belimumab.

Філіппіни - англійська - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - respiratory syncytial virus vaccine (recombinant, adjuvanted) - powder for suspension for injection (im) - 120 mcg